Q-omics provides the consensus-scored COL25A1 profile across patient tissues and cancer cell-line models. COL25A1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, COL25A1 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, COL25A1 RNA expression shows 17,811 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, THCA, and THYM as cancer lineages where COL25A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COL25A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COL25A1 survival associations across molecular data types. COL25A1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COL25A1 RNA expression–survival associations across cancer types. High COL25A1 expression shows unfavorable associations in UCEC and UVM, but favorable associations in UCS, KIRC, ESCA and LIHC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for COL25A1 RNA expression.
This table summarizes COL25A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for COL25A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COL25A1 shows lower tumor expression in THCA, KIRP, COAD, LIHC, BRCA and KICH. The THCA box plot shows higher COL25A1 RNA expression in normal versus tumor tissue (log2 FC = −1.468, t-test p < 0.001).
This table shows molecular features associated with COL25A1 in patient tissues and cancer cell lines. In patient samples, COL25A1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, COL25A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BONE.
